

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

# **MALIGNANT HYPERTHERMIA**

## **ALLELE SPECIFIC EXPRESSION AND MUTATION SCREENING OF THE RYANODINE RECEPTOR 1**

A dissertation presented to Massey University in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Biochemistry

Hilbert Grievink

2009

To be conscious that you are ignorant is a great step to knowledge

Benjamin Disraeli (1804-1881)

# ACKNOWLEDGEMENTS

I would like to take this opportunity to first and foremost thank both my supervisors Assoc. Prof Max Scott and Assoc. Prof. Kathryn Stowell for their expertise, guidance and support during the last three years.

Kathryn, I will be forever grateful for the opportunities you have offered me and helped me realize. I sincerely thank you for presenting me with the possibility to do a PhD after my internship in your research group. You have always been enthusiastic, inspiring and supportive in your advice and guidance. Writing my thesis made me not only realize how much I have learned during these three years but also made me thankful for how much I enjoyed them.

Furthermore I would like to thank everybody in the Twilite Zone for the great times, elaborate pot-luck dinners and awesome lab outings. Will, thanks for all those great games of squash(ing). And Robyn, thank you for an awesome trip around Europe, the good times in the lab, and the much needed distraction (by Robert's emails) from the seemingly endless thesis writing.

I would also like to acknowledge Elaine Langton (Wellington Hospital) and Neil Pollock (Palmerston North Hospital) for supplying blood samples for genomic DNA extractions used for HRM. Thanks also goes to, Jo-Anne Stanton and Chris Mason from the Department of Anatomy and Structural Biology at University of Otago, for their contribution to the 454 data analysis. In addition, I am most grateful to Anthony Thrush and Paula Shields from Roche Diagnostics New Zealand, for their constant technical support over the last three years. Finally, this work would not have been possible without the financial support from the Royal Society of New Zealand Marsden Fund given to Assoc. Prof. Kathryn Stowell.

I am also greatly indebted to my family who have always shown me, love, support and understanding even when I decided to move to the other side of the world. I am looking

forward to being a bit closer to home again. Last but not least I would especially like to thank my wife Liat. Thank you for all your understanding, patience and encouragement over the last three years, all while undertaking your own PhD. I am really sorry for all those times I bored you with my far too detailed monologs of how cool or frustrating my results were. I wish I could promise you it won't happen again.

# ABSTRACT

Malignant hyperthermia (MH) is a dominant skeletal muscle disorder caused by mutations in the ryanodine receptor skeletal muscle calcium release channel (RyR1). Allele-specific differences in RyR1 expression levels might provide insight into the observed incomplete penetrance and variations in MH phenotypes between individuals.

Firstly, an H4833Y allele-specific PCR (AS-PCR) assay was designed that allowed for the relative quantification of the two *RYR1* mRNA alleles in heterozygous samples. In four MHS skeletal muscle samples and two lymphoblastoid cell lines (LCLs), the wild type allele was found to be expressed at higher levels than the mutant RyR1 allele. These differences were not caused by variations in *RYR1* mRNA stabilities. Secondly, high-throughput amplicon sequencing was employed for the quantification of both the T4826I and H4833Y causative MH mutations in heterozygous MHS samples. With the exception of one, all detected H4833Y and T4826I mutation frequencies were about 50%. This included a control, which was constructed and proven to have a 3:1 ratio of the wild type (H4833) versus the mutant (Y4833) *RYR1* allele. This suggested that that the high-throughput amplicon sequencing approach as used here, was not suitable for accurate quantification of the two RyR1 alleles in heterozygous H4833Y MHS samples.

To detect possible variations in RyR1 alleles at the protein level, the RyR1 was to be isolated from microsomes prepared from a H4833Y MHS frozen skeletal muscle tissue. Microsomes isolated from MHS skeletal muscle tissues lacked the immunoreactive band that was believed to be the full length RyR1. Poor muscle quality, due to long term storage was believed to be the main cause of RyR1 depletion.

Faster and less expensive screening methodologies are required for the identification of genetic variants in MH research. Thus, in an additional project inexpensive and high-throughput high-resolution melting (HRM) assays were developed to allow screening of the *RYR1* gene, for mutations associated with MH and/or central core disease (CCD).

# ABBREVIATIONS

ACTA1	Skeletal muscle $\alpha$ -actin
apoCaM	apo-calmodulin
AS1	Allele-specific primer 1
AS2	Allele-specific primer 2
AS-PCR	Allele-specific PCR
ATP	Adenosine triphosphate
AVA-CLI	Amplicon Variant Analyser Command Line Interface
CaM	Calmodulin
CCD	Central core disease
cDNA	Complementary DNA
CICR	Calcium-induced $\text{Ca}^{2+}$ release channel
CLI	Command Line Interface
CSQ	Calsequestrin
Ct values	PCR crossing points
CV	Coefficient of variance
DEPC	Diethylpyrocarbonate
DHPR	Dihydropyridine receptor
DMSO	Dimethylsulfoxide
dNTP	Deoxyribonucleoside triphosphate
dsDNA	Double-stranded DNA
DTT	Dithiothreitol
E	Amplification efficiency
ECCE	Excitation-coupled $\text{Ca}^{2+}$ entry
EC-coupling	Excitation-contraction coupling
EDTA	Ethylenediaminetetraacetic acid
eIF4E	Eukaryotic initiation factor 4E
EMHG	European Malignant Hyperthermia Group
emPCR	Emulsion PCR
ER	Endoplasmic reticulum
FKBP-12	12 kDa FK506 binding protein

FKBP12.6	12.6 kDa FK506 binding protein
gDNA	Genomic DNA
GUI	Graphical user interface
HPRT	Hypoxanthine-guanine-phosphoribosyltransferase
HRC	Histidine-rich calcium binding protein
HRM	High-resolution melting
IP <sub>3</sub> R	Inositol 1,4,5-triphosphate receptors
IPTG	Isopropyl-beta-D-thiogalactopyranoside
IRE	Iron-responsive element
IRES	Internal ribosome entry sites
IVCT	<i>In vitro</i> contracture test
JFM	Junctional face membrane
KcsA	Bacterial K <sup>+</sup> channel
LCL	Lymphoblastoid cell line
m7G	7 methylguanosine
MALDI-TOF	Matrix-assisted laser desorption/ionization time-of-flight
MH	Malignant Hyperthermia
MHE	Malignant hyperthermia equivocal
MHN	Malignant hyperthermia negative
MHS	Malignant hyperthermia susceptible
MHS1 to 5	Malignant hyperthermia loci 1 to 5
miRNA	MicroRNA
MmD	Multi minicore disease
mRNA	Messenger RNA
MthK	<i>Methanobacterium autotrophicum</i> potassium channel
MYH7	Beta-myosin heavy chain
NAMHG	North American Malignant Hyperthermia Group
NTC	Non template control
ORF	Open reading frame
PABP	Poly(A)-binding protein
PMCA	Plasma membrane calcium ATPase
PPi	Pyrophosphate



RT-PCR	Reverse transcription-PCR
RyR1	Skeletal muscle ryanodine receptor 1 isoform
RyR2	Cardiac muscle ryanodine receptor 2 isoform
RyR3	Brain ryanodine receptor 3 isoform
SEPN1	Selenoprotein gene
SERCA	Sarco-Endoplasmic Reticulum Ca <sup>2+</sup> -ATPase
SNP	Single nucleotide polymorphism
SOCE	Store-operated Ca <sup>2+</sup> entry
SR	Sarcoplasmic reticulum
sstDNA	Single strand template DNA
T <sub>m</sub>	Melting temperature
TRPC	Transient receptor potential channel
T-tubule	Transverse-tubule
UTR	Untranslated region
XALD	X-linked adrenoleukodystrophy
X-Gal	5-Bromo-4-Chloro-3-Indolyl-BD-Galactopyranoside

# LIST OF FIGURES

Figure 1.1: The mutation hotspots on the <i>RYR1</i> gene. _____	20
Figure 1.2: Proposed mechanism for induction of MH caused by abnormalities in the $\text{Ca}^{2+}$ release channel of skeletal muscle sarcoplasmic reticulum. _____	24
Figure 1.3: Possible mechanisms of how RyR1 mutations can affect intracellular calcium concentrations. _____	27
Figure 1.4: Side view of the three dimensional structure of RyR1. _____	30
Figure 1.5: Solid body representations of the three isoforms of ryanodine receptor. __	31
Figure 1.6: Schematic representation of the major components of the skeletal muscle triad. _____	35
Figure 2.1: Schematic representation of the QuickChange® Site-Directed Mutagenesis procedure. _____	50
Figure 3.1: Dye redistribution during melting might interfere with heteroduplex detection. _____	66
Figure 3.2: Visualizing of the amplified genomic DNA for cloning. _____	68
Figure 3.3: <i>EcoR1</i> digests of 4861 transformants compared to untreated 4861 plasmid construct. _____	69
Figure 3.4: Representative results of the mutagenesis PCR products after <i>Dpn1</i> digestion. _____	70
Figure 3.5: HRM data analysis of the 4861 61 bp amplicons, using the LightCycler® 480 Gene Scanning Software. _____	73
Figure 3.6: Difference plots of gDNA HRM analyses of the 4861 81 bp amplicons. _	74
Figure 3.7: Difference plots of gDNA HRM analyses of the 4826 77 bp amplicons. _	75
Figure 3.8: Difference plots of gDNA HRM analyses of the 4833 78 bp amplicons. _	76
Figure 3.9: HRM analysis of possible SNP genotypes at the 4861 position, using the LightCycler® 480 HRM Master (81 bp amplicons). _____	77
Figure 3.10: HRM analysis of possible SNP genotypes at the 4861 position by adding wild type DNA amplicons, using the LightCycler® 480 HRM Master (81 bp amplicons). _____	78

Figure 3.11: HRM analysis of possible SNP genotypes at the 4861 position, using the LightCycler® 480 HRM Master (61 bp amplicons).	79
Figure 4.1: Allele specific differences in gene expression.	84
Figure 4.2: Principle of the AS-PCR of <i>RYR1</i> cDNA.	85
Figure 4.3: Visualizing the amplified cDNA fragments used for cloning.	87
Figure 4.4 Transformants before and after digest with <i>EcoR1</i> .	88
Figure 4.5: Testing allele-specific PCR primer specificities using plasmid constructs.	89
Figure 4.6: Visualizing the AS-PCR products.	89
Figure 4.7: Real-time PCR results for the determination of reverse transcription linearity.	93
Figure 4.8: Determination of the PCR amplification efficiency of mutant <i>RYR1</i> cDNA.	94
Figure 4.9: Linear relationship of cDNA synthesis as a function of RNA content.	95
Figure 4.10: Constructed standard curves for the determination of the PCR amplification efficiencies.	97
Figure 4.11: Difference plot generated by HRM analysis of the 4833 78 bp amplicons.	104
Figure 4.12: Constructed standard curves for the determination of the PCR amplification efficiencies.	106
Figure 4.13: mRNA expression levels in LCL #1295 after actinomycin D incubations.	108
Figure 5.1: Clonal amplification of annealed DNA fragments.	115
Figure 5.2: Bead deposition into PicoTiterPlate.	116
Figure 5.3: Sequencing-by-synthesis.	117
Figure 5.4: Schematic representation of a PCR product generated by the amplification using bar coded fusion primers.	119
Figure 5.5: Visualizing the amplified products used for library preparation.	124
Figure 5.6: Visualizing the amplified products from serially diluted template used for library preparation.	129
Figure 5.7: Visualizing cDNA PCR products generated for allele frequency determination control.	129
Figure 6.1: Trypsin cleavage sites around the 4833 amino acid.	139

Figure 6.2: Separation of microsomal proteins prepared from a frozen MHN skeletal muscle tissue #1482. _____	141
Figure 6.3: Separation of microsomal proteins prepared from a frozen MHN skeletal muscle tissue #1482. _____	143
Figure 6.4: Separation of microsomal proteins prepared from a frozen skeletal muscle tissues #1482 (MHN) and #145 (MHS). _____	144
Figure 6.5: Separation of microsomal proteins prepared from a frozen MHS skeletal muscle tissues #835 and #116. _____	146
Figure 6.6: Separation of microsomal proteins prepared from a frozen MHN skeletal muscle tissue #66. _____	147
Figure V.1: Screen shot of the file that contains the Reference sequence in tsv-format. _____	177
Figure V.2: Screen shot of the file that contains the specified Amplicon in tsv-format. _____	178
Figure V.3: Screen shot of the file that contains the specified Variants in tsv-format.	178
Figure V.4: Screen shot of the file that contains the specified Sample in tsv-format.	179
Figure V.5: Screen shot of the file that was used to associate the Amplicons with Samples in tsv-format. _____	180
Figure V.6: Screen shot of the file that contains the table (in tsv-format) that was used to upload the ACGA bar coded sequences. _____	181

# LIST OF TABLES

Table 2.1: Reaction components of the standard PCR protocol _____	46
Table 2.2: Cycle parameters of standard PCR _____	46
Table 2.3: Reaction components of the pGEM®-T Easy cloning protocol _____	47
Table 2.4: Reaction components of the <i>Eco</i> RI digestion protocol _____	49
Table 2.5: Reaction components of the site directed mutagenesis protocol _____	51
Table 2.6: Site directed mutagenesis cycle parameters _____	51
Table 2.7: Reaction components of the TURBO DNase treatment protocol _____	53
Table 2.8: Reaction components for priming RNA with oligo(d)Ts _____	54
Table 2.9: Reaction components of the oligo(d)T primer extension protocol _____	54
Table 2.10: Reaction components for the LightCycler® 480 HRM Master HRM protocol _____	55
Table 2.11: Reaction components for the LCGreen PLUS HRM protocol _____	56
Table 2.12: PCR and HRM parameters _____	57
Table 2.13: Reaction components for the allele specific PCR protocol _____	58
Table 2.14: PCR parameters for allele specific PCR _____	58
Table 3.1: Mutagenic primers for the 4861 amino acid _____	70
Table 3.2: HRM primer sequences, primer concentrations and amplicon sizes _____	71
Table 4.1: Primers used in the allele-specific PCR assay _____	86
Table 4.2: Relative allele frequencies using engineered plasmid constructs _____	90
Table 4.3: Summary of the linearity of the reverse transcription reactions _____	96
Table 4.4: Mean PCR amplification efficiencies (n=4) _____	98
Table 4.5: Intra-assay variability of real-time PCR when screening #470 (n=3) _____	99
Table 4.6: Inter-assay variability of real-time PCR when screening #470 _____	99
Table 4.7: Relative <i>RYR1</i> transcript abundance ratios in muscle tissue (n=3) _____	101
Table 4.8: Data from the <i>in vitro</i> contracture test _____	101
Table 4.9: Real-time PCR results for the after prolonged culturing of LCL #1051 _____	102
Table 4.10: Relative <i>RYR1</i> transcript abundance ratios after prolonged culturing of LCL #1051 _____	103
Table 4.11: Summary of the linearity of the reverse transcription determinations _____	105

Table 4.12: Mean PCR amplification efficiencies (n=4) _____	106
Table 4.13: Average real-time PCR results of three independent mRNA stability assays for _____	107
Table 4.14: Relative <i>RYR1</i> transcript abundance ratios of LCL #1295 after incubation with actinomycin D _____	109
Table 4.15: Relative <i>RYR1</i> transcript abundance ratios of LCL #1333 after incubation with actinomycin D _____	109
Table 5.1: Ten sample DNA library and the bar coded fusion primers used _____	120
Table 5.2: Seven sample DNA library and the bar coded fusion primers used _____	121
Table 5.3: Detected SNP frequencies of the ten sample DNA library _____	126
Table 5.4: Comparison of the detected RyR1 expression levels using high-throughput sequencing or allele-specific PCR _____	127
Table 5.5: Relative allele frequencies using purified PCR products _____	131
Table 5.6: Detected SNP frequencies of the seven sample DNA library _____	132

# TABLE OF CONTENTS

Acknowledgements	iii
Abstract	v
Abbreviations	vi
List of figures	ix
List of tables	xii
1. Introduction	18
1.1 Malignant Hyperthermia	18
1.1.1 History of Malignant Hyperthermia	18
1.1.2 Manifestations of Malignant Hyperthermia	19
1.1.3 Molecular genetics of Malignant Hyperthermia	20
1.1.4 Associated myopathies	21
1.1.5 Physiological basis of malignant hyperthermia	22
1.1.6 Hypersensitivity of MHS RyR1 channels	24
1.1.7 Diagnostic testing	27
1.2 Ryanodine receptor	29
1.3 Maintaining intracellular calcium homeostasis	32
1.3.1 Endogenous RyR1 modulators	32
1.3.2 Proteins involved in SR calcium storage	33
1.3.3 Proteins involved in SR calcium release	34
1.4 The role of gene expression in human disease	38
1.5 PhD project outline	41
2. Materials and methods	43
2.1 Materials	43
2.2 Methods	44
2.2.1 Genomic DNA isolation	44
2.2.2 Standard PCR protocol	45
2.2.3 Cloning of PCR products	47

2.2.4 Preparation of heat shock competent cells _____	47
2.2.5 Transformation _____	48
2.2.6 Rapid boil plasmid preparation _____	48
2.2.7 Site-directed mutagenesis _____	49
2.2.8 Isolation of RNA _____	52
2.2.9 DNase treatment of the isolated RNA _____	53
2.2.10 First-strand cDNA synthesis _____	54
2.2.11 High-Resolution Melting reaction conditions _____	55
2.2.12 Allele-specific PCR reaction conditions _____	57
2.2.13 Tissue culture _____	59
2.2.14 Measuring DNA concentrations using the Qubit fluorometer _____	60
2.2.15 Preparation of crude microsomes from skeletal muscle _____	61
2.2.16 Polyacrylamide gel electrophoresis _____	62
2.2.17 Western blot analysis _____	63
2.2.18 DNA sequencing _____	64
3. High-resolution melting _____	65
3.1 Introduction _____	65
3.2 Assay design _____	67
3.2.1 DNA samples used for assay validation _____	67
3.2.2 PCR and high resolution melting conditions _____	71
3.2.3 Data analysis _____	71
3.3 Results _____	74
3.3.1 Genomic DNA samples _____	74
3.3.2 Engineered plasmid constructs _____	76
3.4 Discussion _____	79
4. Allele-specific PCR _____	83
4.1 Introduction _____	83
4.2 Assay design _____	85
4.2.1 Primer design _____	85
4.2.2 Testing allele specificity _____	86
4.2.3 Validation of allele-specific PCR assay using engineered plasmid constructs _____	90
4.2.4 Relative quantification of RyR1 cDNA _____	91



4.3 Results	94
4.3.1 Screening muscle tissues	94
4.3.2 mRNA stability assays	101
4.4 Discussion	109
5. High-throughput amplicon sequencing	114
5.1 Introduction	114
5.2 Assay design	119
5.2.1 Bar coded fusion primers	119
5.2.2 DNA samples	121
5.2.3 PCR conditions and sample preparation	122
5.3 Results	123
5.3.1 Ten sample DNA library	123
5.3.2 Seven sample DNA library	128
5.4 Discussion	133
6. Allelic variation at the protein level	137
6.1 Introduction	137
6.2 Assay design	138
6.3 Results	139
6.4 Discussion	147
7. Summary and future directions	150
7.1 SNP detection using HRM	150
7.2 Allele-specific ryanodine receptor 1 expression	150
7.2.1 Allele specific <i>RYR1</i> mRNA expression	150
7.2.3 Allele-specific RyR1 expression	153
References	155
Appendices	171
Appendix I: PGEM®-T Easy Vector map and sequence reference points.	171
Appendix II: Sequence results of the engineered 4861 HRM templates	172
Appendix III: Partial C-terminal amino acid and cDNA sequence of the <i>RYR1</i>	174
Appendix IV: Sequence results of the engineered 4833 plasmid constructs	175
Appendix V: Workflow for using the Amplicon Variant Analyser Command Line Interface	176

Appendix VI: Amplicon Variant Analyser Command Line Interface output files _____	184
Appendix VII: Results of RyR1 trypsin cleavage _____	203